These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22674642)

  • 1. Modeling and prediction of subject accrual and event times in clinical trials: a systematic review.
    Zhang X; Long Q
    Clin Trials; 2012 Dec; 9(6):681-8. PubMed ID: 22674642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Joint monitoring and prediction of accrual and event times in clinical trials.
    Zhang X; Long Q
    Biom J; 2012 Nov; 54(6):735-49. PubMed ID: 22907686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian accrual modeling and prediction in multicenter clinical trials with varying center activation times.
    Liu J; Wick J; Jiang Y; Mayo M; Gajewski B
    Pharm Stat; 2020 Sep; 19(5):692-709. PubMed ID: 32319194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stochastic modeling and prediction for accrual in clinical trials.
    Zhang X; Long Q
    Stat Med; 2010 Mar; 29(6):649-58. PubMed ID: 20082363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian modeling and prediction of accrual in multi-regional clinical trials.
    Deng Y; Zhang X; Long Q
    Stat Methods Med Res; 2017 Apr; 26(2):752-765. PubMed ID: 25367100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accrual by groups in trials with discrete-time survival endpoints.
    Jóźwiak K; Moerbeek M
    Clin Trials; 2013 Feb; 10(1):32-42. PubMed ID: 23203992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical modeling and prediction of clinical trial recruitment.
    Lan Y; Tang G; Heitjan DF
    Stat Med; 2019 Mar; 38(6):945-955. PubMed ID: 30411375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accrual Prediction Program: A web-based clinical trials tool for monitoring and predicting accrual for early-phase cancer studies.
    Liu J; Wick JA; Mudaranthakam DP; Jiang Y; Mayo MS; Gajewski BJ
    Clin Trials; 2019 Dec; 16(6):657-664. PubMed ID: 31451012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical considerations for estimating clinical trial accrual periods: application to a multi-center effectiveness study.
    Carter RE; Sonne SC; Brady KT
    BMC Med Res Methodol; 2005 Mar; 5():11. PubMed ID: 15796782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting analysis time in event-driven clinical trials with event-reporting lag.
    Wang J; Ke C; Jiang Q; Zhang C; Snapinn S
    Stat Med; 2012 Apr; 31(9):801-11. PubMed ID: 22344853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and monitoring of survival trials based on restricted mean survival times.
    Luo X; Huang B; Quan H
    Clin Trials; 2019 Dec; 16(6):616-625. PubMed ID: 31450951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian accrual prediction for interim review of clinical studies: open source R package and smartphone application.
    Jiang Y; Guarino P; Ma S; Simon S; Mayo MS; Raghavan R; Gajewski BJ
    Trials; 2016 Jul; 17(1):336. PubMed ID: 27449769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting event times in clinical trials when randomization is masked and blocked.
    Donovan JM; Elliott MR; Heitjan DF
    Clin Trials; 2007; 4(5):481-90. PubMed ID: 17942464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Power and sample size considerations in clinical trials with competing risk endpoints.
    Maki E
    Pharm Stat; 2006; 5(3):159-71. PubMed ID: 17080750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring event times in early phase clinical trials: some practical issues.
    Thall PF; Wooten LH; Tannir NM
    Clin Trials; 2005; 2(6):467-78. PubMed ID: 16422307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Gini coefficient as a measure for understanding accrual inequalities in multicenter clinical studies.
    Haidich AB; Ioannidis JP
    J Clin Epidemiol; 2004 Apr; 57(4):341-8. PubMed ID: 15135834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing phase II studies in cancer with time-to-event endpoints.
    Owzar K; Jung SH
    Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity to censored-at-random assumption in the analysis of time-to-event endpoints.
    Lipkovich I; Ratitch B; O'Kelly M
    Pharm Stat; 2016 May; 15(3):216-29. PubMed ID: 26997353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.